The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The National Malaria Programme in Guinea-Bissau recommends paracetamol for all children treated for malaria. We, the investigators of the Bandim Health Project, want to evaluate whether this treatment has any effect on:

* the well-being of the child;
* the parasite clearance time; and
* the rate of a re-appearance of parasites during 35 days of follow-up.

Children presenting at Bandim Health Centre with malaria will be treated with chloroquine plus paracetamol or chloroquine plus placebo. Blood samples will be obtained daily for the first 4 days and then once a week until day 35.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Paracetamol on Kidney Function in Severe Malaria

NCT04251351

Severe Malaria Malaria,Falciparum Acute Kidney Injury +1 more

RECRUITING PHASE3

Chloroquine and Amodiaquine for Treatment of Malaria in Children

NCT00137514

Malaria, Falciparum

COMPLETED PHASE4

Aggressive Antipyretics for Fever Reduction in CNS Malaria

NCT03399318

Malaria Seizures Coma +3 more

COMPLETED PHASE2

Treatment of Fever Due to Malaria With Ibuprofen

NCT00167713

Fever

COMPLETED PHASE4

Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria

NCT00329134

Malaria

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Cochrane Review was unable to show a superior antipyretic effect of paracetamol compared with placebo in febrile children. Recent research suggests that the time to parasite clearance in non-severe malaria is longer in children being given paracetamol. As the costs associated with the use of paracetamol is not trivial and the risk of adverse effects is not negligible, we want to evaluate the effects of paracetamol on:

* the well-being of the child;
* the parasite clearance time; and
* the recrudescence rate.

Children presenting at Bandim Health Centre with symptoms of malaria and a malaria film showing mono-infection with P.falciparum will, following consent to participate, randomly be allocated to treatment with chloroquine and paracetamol or with chloroquine and placebo.

Blood samples will be obtained daily for the first 4 days. The children will be visited and a malaria film taken on day 7 and then weekly until day 35. On inclusion and whenever parasitaemia is detected a capillary blood sample will be taken for PCR analyses to be able to distinguish re-infection from recrudescence.

During follow-up children are recommended to present at the health centre in case of persistent fever or any other symptoms. Examination and treatment will be free of charge. Whenever a child has re-infection sulfadoxine/pyrimethamine will be used for re-treatment following the recommendation of the National malaria Programme.

After the inclusion of 80 children a preliminary analysis will be performed. If 50% or more of the children in any of the study arms have reappearing parasitaemia the study will be terminated.

If the parasite clearance time and especially the recrudescence rate is higher for children being given paracetamol the current recommendation from the National Malaria Programme should be reconsidered. If children treated with paracetamol feel better during the acute illness making it more likely for them to have en adequate intake of food and liquid this benefit should be considered in the evaluation of the current recommendations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria Falciparum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 Paracetamol

Paracetamol as per protocol

Group Type EXPERIMENTAL

acetaminophen (paracetamol)

Intervention Type DRUG

Paracetamol tablets, 50 mg/kg/day for 3 days.

2 Placebo

Inactive placebo as per protocol.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acetaminophen (paracetamol)

Paracetamol tablets, 50 mg/kg/day for 3 days.

Intervention Type DRUG

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \< 15 years of age
* Presenting at Bandim Health Centre
* Symptoms suggestive of malaria
* At least 20 P. falciparum parasites per 200 leukocytes
* Live in Bandim (to enable follow-up)

Exclusion Criteria

* Severely ill children considered to need the services of a hospital by the doctor in charge
* Previous idiosyncratic reactions to chloroquine or paracetamol

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No